chloroquine has been researched along with zithromax in 133 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (3.01) | 18.2507 |
2000's | 17 (12.78) | 29.6817 |
2010's | 35 (26.32) | 24.3611 |
2020's | 77 (57.89) | 2.80 |
Authors | Studies |
---|---|
Dunne, MW; Fidock, DA; Nkrumah, LJ; Sacchettini, JC; Sidhu, AB; Sun, Q | 1 |
Fukuda, M; Jongsakul, K; Knirsch, C; Krudsood, S; Leowattana, W; Looareesuwan, S; Miller, RS; Noedl, H; Ohrt, C; Sriwichai, S; Tangpukdee, N; Thanachartwet, W; Yingyuen, K | 1 |
Dennull, RA; Gerena, L; Johnson, JD; Lopez-Sanchez, M; Roncal, NE; Waters, NC | 1 |
Dahl, EL; Rosenthal, PJ | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Fuehrer, HP; Haque, R; Hofecker, V; Khan, WA; Ley, B; Noedl, H; Siedl, A; Starzengruber, P; Thriemer, K; Wernsdorfer, WH | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Ellis, W; Hutinec, A; Milhous, W; Ohrt, C; Rupčić, R; Schönfeld, ZI; Smith, KS; Ziher, D | 1 |
Ager, A; Alihodžić, S; Bukvić Krajačić, M; Ellis, WY; Fajdetić, A; Hutinec, A; Ivezić-Schönfeld, Z; Jelić, D; Landek, G; Mesić, M; Milhous, WK; Ohrt, C; Padovan, J; Perić, M; Rupčić, R; Smith, KS; Spaventi, R; Ziher, D | 1 |
Alihodžić, S; Ferrer, S; Herreros, E; Landek, G; Perić, M; Pešić, D; Spaventi, R; Starčević, K; Toplak, A | 1 |
Alihodžić, S; Almela, MJ; Herreros, E; Jelić, D; Perić, M; Pešić, D; Spaventi, R; Starčević, K; Toplak, A; Vidal, J | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Bello, AM; Crandall, IE; Kain, KC; Kotra, LP; Malhotra, P; Mohmmed, A; Pai, EF; Wasilewski, E | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Agard, DA; Ashworth, A; Barrio-Hernandez, I; Batra, J; Beltrao, P; Bennett, MJ; Bohn, M; Bouhaddou, M; Braberg, H; Broadhurst, DJ; Cai, Y; Cakir, M; Calviello, L; Cavero, DA; Chang, JCJ; Chorba, JS; Craik, CS; d'Enfert, C; Dai, SA; Eckhardt, M; Emerman, M; Fabius, JM; Fletcher, SJ; Floor, SN; Foussard, H; Frankel, AD; Fraser, JS; Fujimori, DG; Ganesan, SJ; García-Sastre, A; Gordon, DE; Gross, JD; Guo, JZ; Haas, K; Haas, P; Hernandez-Armenta, C; Hiatt, J; Huang, XP; Hubert, M; Hüttenhain, R; Ideker, T; Jacobson, M; Jang, GM; Jura, N; Kaake, RM; Kim, M; Kirby, IT; Klippsten, S; Koh, C; Kortemme, T; Krogan, NJ; Kuzuoglu-Ozturk, D; Li, Q; Liboy-Lugo, J; Lin, Y; Liu, X; Liu, Y; Lou, K; Lyu, J; Mac Kain, A; Malik, HS; Mathy, CJP; McGregor, MJ; Melnyk, JE; Memon, D; Meyer, B; Miorin, L; Modak, M; Moreno, E; Mukherjee, S; Naing, ZZC; Noack, J; O'Meara, MJ; O'Neal, MC; Obernier, K; Ott, M; Peng, S; Perica, T; Pilla, KB; Polacco, BJ; Rakesh, R; Rathore, U; Rezelj, VV; Richards, AL; Roesch, F; Rosenberg, OS; Rosenthal, SB; Roth, BL; Roth, TL; Ruggero, D; Safari, M; Sali, A; Saltzberg, DJ; Savar, NS; Schwartz, O; Sharp, PP; Shen, W; Shengjuler, D; Shi, Y; Shoichet, BK; Shokat, KM; Soucheray, M; Stroud, RM; Subramanian, A; Swaney, DL; Taunton, J; Tran, QD; Trenker, R; Tummino, TA; Tutuncuoglu, B; Ugur, FS; Vallet, T; Venkataramanan, S; Verba, KA; Verdin, E; Vignuzzi, M; von Zastrow, M; Wang, HY; Wankowicz, SA; Wenzell, NA; White, KM; Xu, J; Young, JM; Zhang, Z; Zhou, Y | 1 |
Beus, M; Fallarero, A; Patel, JZ; Savijoki, K; Yli-Kauhaluoma, J; Zorc, B | 1 |
Gingras, BA; Jensen, JB | 2 |
Andersen, SL; Ballou, WR; Foulds, G; Hall, T; Heppner, DG; Kuschner, RA; Sadoff, JC; Schneider, I; Schuster, B; Wellde, BT | 1 |
Davis, TM | 1 |
Puri, SK; Singh, N | 1 |
Kain, KC; Keystone, JS; Shanks, GD | 1 |
Brasseur, R; Chanteux, H; Mingeot-Leclercq, MP; Paternotte, I; Sonveaux, E; Tulkens, PM | 1 |
Benner, R; Bhattacharyya, PC; Dev, V; Dunne, MW; Lakhani, J; Lele, C; Mohapatra, MK; Patel, K; Patki, K; Shukla, M; Singh, N; Valecha, N | 1 |
Adak, T; Bhattacharyya, PC; Dev, V; Devi, CU; Dunne, MW; Lakhani, J; Lele, C; Mohapatra, MK; Patel, K; Patki, K; Shukla, M; Singh, N; Valecha, N; Yadav, RS | 1 |
Bramson, CR; Cook, JA; Randinitis, EJ; Wesche, DL | 1 |
Deng, S; Duncan, JN; Dunne, M; Fossa, AA; Wisialowski, T | 1 |
Basque, J; Cantin, AM; Leduc, R; Martel, M | 1 |
Chandramohan, D; Chico, RM; Greenwood, B; Pittrof, R | 1 |
Baiwog, F; Davis, TM; Gomorai, S; Griffin, S; Ilett, KF; Kandai, J; Karunajeewa, HA; Kose, K; Mueller, I; O'Halloran, SJ; Rogerson, SJ; Salman, S; Siba, P; Winmai, J | 1 |
Chandramohan, D; Chico, RM | 2 |
Terlouw, DJ; van Eijk, AM | 1 |
Chandra, R; Djimde, A; Fidock, DA; Gore, K; Hardink, J; Henrich, PP; Johnson, D; Lin, J; O'Brien, C; Pereira, MR; Sidhu, AB; Van Deusen, J; Wele, M | 1 |
Friesen, J; Matuschewski, K | 1 |
Dzinjalamala, FK; Laufer, MK; Laurens, MB; Masonga, R; Nyirenda, OM; Plowe, CV; Stokes-Riner, A; Taylor, TE; Thesing, PC | 1 |
Du Plessis, LH; Kotzé, AF; Maritz, MM; van Niekerk, AC | 1 |
Banjanac, M; Eraković Haber, V; Munić, V; Nujić, K; Polančec, D | 1 |
Goodman, CD; Gramajo, H; Labadie, GR; McFadden, GI; Peirú, S; Rodríguez, E; Useglio, M | 1 |
Chandra, RS; Duparc, S; Orazem, J; Robbins, J; Ubben, D; Vandenbroucke, P | 1 |
Kaushik, M; Mahajan, SK; Raina, R; Thakur, P | 1 |
Chandra, R; Mould, DR; Tensfeldt, TG; Zhao, Q | 1 |
Brouwer, KL; Ferslew, BC | 1 |
Holtz, LR; Tarr, PI | 1 |
Claassen, CW; Dzinjalamala, FK; Gilliams, EA; Jumare, J; Laufer, MK; Nyirenda, OM; Plowe, CV; Taylor, T; Thesing, PC; Tracy, LA | 1 |
Chandra, R; Dieng, Y; Djimdé, AA; Dunne, MW; Kain, KC; Mugyenyi, P; Mulenga, M; Oduro, AR; Ogutu, B; Robbins, J; Sagara, I; Sarkar, S; Sie, A; Tiono, AB; Wasunna, M | 1 |
Bardaji, A; Betuela, I; Hanieh, S; Kongs, C; Lufele, E; Menendez, C; Mueller, I; Ome-Kaius, M; Robinson, LJ; Rogerson, SJ; Rosanas-Urgell, A; Samol, P; Schofield, L; Siba, P; Singirok, D; Suen, CS; Sui, D; Umbers, AJ; Unger, HW; Wangnapi, RA; Wapling, J | 1 |
Ansah, P; Chandra, R; Djimde, AA; Ogutu, B; Penali, LK; Robbins, J; Sagara, I; Sie, A; Tiono, AB; Zhao, Q | 1 |
Brown, GV; Hasang, W; Mueller, I; Randall, LM; Rogerson, SJ; Siba, PM; Teo, A; Unger, HW | 1 |
Ayoub, A; Duparc, S; Kamiza, S; Kimani, J; Orrico, R; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P | 1 |
Ayoub, A; Duparc, S; Kimani, J; Mtove, GA; Phiri, K; Robbins, J; Rojo, R; Vandenbroucke, P; Zhao, Q | 1 |
Chen, H; Huang, S; Jin, L; Li, J; Ni, Q; Pan, C; Yao, L; Zhang, L | 1 |
Agarwal, P; Anvikar, AR; Pillai, CR; Srivastava, K | 1 |
Juurlink, DN | 1 |
Cutrell, JB; Jodlowski, TZ; Monogue, ML; Sanders, JM | 1 |
Clerc, A; Gendrot, M; Javelle, E; Pradines, B; Savini, H | 1 |
Aajal, A; Ait Brik, A; Ammour, O; Benajiba, C; El Boussadani, B; El Hangouch, J; Oussama, B; Oussama, O; Raissuni, Z; Tahiri, N | 1 |
Abena, PM; Adejumo, P; Bottieau, E; Decloedt, EH; Eholie, SP; Kallay, O; Mills, EJ; Muyembe TamFum, JJ; Nachega, JB; Sam-Agudu, NA; Seydi, M; Suleman, F; Zumla, A | 1 |
Brown, JD; Cicali, B; Henriksen, CH; Sarayani, A | 1 |
Albuquerque, BC; Alexandre, MAA; Baía-da-Silva, D; Balieiro, AAS; Bassat, Q; Borba, MGS; Brito, M; Brito-Sousa, JD; Croda, J; Daniel-Ribeiro, CT; Fontes, CJ; Guerra, MVF; Hajjar, LA; Lacerda, MVG; Melo, GC; Monteiro, WM; Mourão, MPG; Naveca, FG; Nogueira, ML; Pacheco, AGF; Pinto, RC; Romero, GAS; Sampaio, VS; Santos, JDO; Schwarzbold, A; Siqueira, AM; Val, FFA; Xavier, MS | 1 |
Drici, MD; Funck-Brentano, C; Nguyen, LS; Roden, DM; Salem, JE | 1 |
Beldner, S; Chang, D; Chinitz, J; Epstein, LM; Gabriels, J; Goldner, B; Ismail, H; John, R; Mahmood, E; Makker, P; Mansoor, A; Mitra, R; Mountantonakis, S; Saleh, M; Skipitaris, N; Soo Kim, B; Willner, J | 1 |
Becker, G; El-Hage, W; Hingray, C; Javelot, H; Meyer, G; Michel, B | 1 |
Chen, T; Chen, Y; Ferrari, V; Han, Y; Jagasia, D; Kang, Y; Mui, D; Scherrer-Crosbie, M | 1 |
Genoni, G; Kozel, D; Monzani, A; Pistis, G; Scopinaro, A; Secco, GG | 1 |
Seftel, MD | 1 |
Adebayo, AI; Adeoye, AO; Olaoye, IF; Oso, BJ; Tijjani, H | 1 |
Wong, A | 1 |
Thai, TN; Vouri, SM; Winterstein, AG | 1 |
Acunzo, R; Asensio, E; Saad, EB; Sáenz, LC; Uribe, W | 1 |
Abraham, GM; Andrews, R; Bledsoe, TA; Centor, RM; Etxeandia-Ikobaltzeta, I; Forciea, MA; Haeme, R; Humphrey, LL; Jokela, JA; Kansagara, DL; Marcucci, M; Miller, MC; Obley, AJ; Qaseem, A; Yost, J | 1 |
Caceres, SM; Grimm, XA; Malcolm, KC; Nick, JA; Poch, KR; Pohl, K; Rysavy, N; Saavedra, M | 1 |
Azizi, M; Benhaddou, H; El Amrani, R; Elbakkaoui, M; Kamaoui, I; Lahfaoui, M | 1 |
Campos, L; Gouveia, CC | 1 |
Berni-Betancourt, A; Carrasco, OF; Medeiros-Domingo, A | 1 |
Medina, MT; Moncada, SS | 1 |
Abraham, GM; Etxeandia-Ikobaltzeta, I; Forciea, MA; Humphrey, LL; Jokela, JA; Miller, MC; Obley, AJ; Qaseem, A; Yost, J | 1 |
Kazama, I | 1 |
Budnitz, DS; Lovegrove, M; Shehab, N | 1 |
Daily, J; Di Biase, L; Ferrick, KJ; Fisher, JD; Greige, N; Hsia, BC; Khokhar, AS; Krumerman, A; Quiroz, JA | 1 |
Allwood, B; Blockman, M; Decloedt, EH; Koegelenberg, CFN; Parker, A; Reuter, H; Taljaard, J | 1 |
Abi Jaoude, J; El Alam, MB; Garcia Garcia, CJ; Kouzy, R; Ludmir, EB; Taniguchi, CM | 1 |
Acharya, Y; Sultan, S | 1 |
Etxeandia-Ikobaltzeta, I; Humphrey, LL; Qaseem, A; Yost, J | 1 |
Braz, HLB; de Moraes, MEA; Jorge, RJB; Marinho, AD; Monteiro, HSA; Moraes Filho, MO; Silveira, JAM | 1 |
Munic Kos, V; Norgren, K; Norinder, U; Tuck, A | 1 |
Chicharro, P; De Argila, D; Llamas-Velasco, M; Muñoz-Aceituno, E; Muñoz-Hernández, P; Rodríguez-Jiménez, P | 1 |
Czeszko-Paprocka, H; Dyda, T; Horban, A; Kowalska, JD; Pihowicz, A; Podlasin, RB; Thompson, M; Wojtycha-Kwaśnica, B | 1 |
Fiolet, T; Guihur, A; Mahamat-Saleh, Y; Mulot, M; Peiffer-Smadja, N; Rebeaud, ME | 2 |
Calender, A; Israel-Biet, D; Pacheco, Y; Valeyre, D | 1 |
Fatima, S; Fatima, U; Hassan, MI; Rizvi, SSA | 1 |
Antonijević Miljaković, E; Antonijević, B; Baralić, K; Buha Djordjevic, A; Ćurčić, M; Jorgovanović, D; Živančević, K; Đukić-Ćosić, D | 1 |
Bennett, J; Cicatelli, S; DeLuca, J; Duncan, EH; Hamer, M; Hutter, J; Kreishman-Deitrick, M; Lee, C; Livezey, J; Mills, K; Moon, JE; Morrison, M; Oliver, T; Poon, L; Sedegah, M; Selig, D; Sikaffy, A; Sousa, J; Tosh, D; Twomey, P; Vuong, C; Waterman, P | 1 |
Jones, CW; Platts-Mills, TF; Woodford, AL | 1 |
Kim, D; Kim, JH; Kim, JS; Kim, YS; Lee, SY; Yoon, JW; Yu, S | 1 |
Grundmark, B; Vidlin, SH; Watson, S; Zekarias, A | 1 |
Shah, RR | 1 |
Ahuka-Mundeke, S; Bongo-Pasi Nswe, C; Hermans, MP; Ishoso, DK; Kayembe, JM; Kolié, MC; Machekano, RN; Madinga, JN; Mavungu Landu, DJ; Mbala-Kingebeni, P; Mbuyi, GM; Mellors, JW; Mills, EJ; Mofenson, L; Mukeba Tshialala, D; Mukendi, S; Muyembe-Tamfum, JJ; Nachega, JB; Nkwembe, EN; Nsio, JM; Otokoye, JO; Sam-Agudu, NA; Smith, G; Tshiasuma Pipo, M; Zumla, A | 1 |
AlDosary, O; Garbati, MA; Gerberi, D; Kashour, T; Kashour, Z; Murad, MH; Riaz, M; Sohail, MR; Tlayjeh, H; Tleyjeh, IM | 1 |
Alihodžić, S; Angulo-Barturen, I; Banjanac, M; Bencetić Mihaljević, V; Bukvić, M; Eraković Haber, V; Fajdetić, A; Ferrer-Bazaga, S; Gamo, FJ; Gargallo-Viola, D; Herreros, E; Jiménez-Díaz, MB; Kessler, A; Martínez, MS; Mathis, A; Munic Kos, V; Padovan, J; Peric, M; Pešić, D; Spaventi, R | 1 |
Niburski, K; Niburski, O | 1 |
Atakla, HG; Houinato, DS; Noudohounsi, MMUD; Noudohounsi, WC; Sacca, H; Tassiou, NRA | 1 |
Campana, C; Dariolli, R; Gutierrez, A; Irurzun-Arana, I; Pullinger, TK; Sobie, EA; Varshneya, M | 1 |
Ahmed, AAQ; Bakadia, BM; Boni, BO; He, F; Lamboni, L; Mukole, BM; Souho, T; Ullah, MW; Yang, G | 1 |
Almaghraby, A; Beshir, H; Ghazy, RM; Kamal, A; Moursi, A; Ramadan, A; Shaaban, R; Taha, SHN | 1 |
Dingding, Q; Jiangfang, L; Yujia, W; Zequn, Z | 1 |
Costa, KD; Gurung, B; Hajjar, RJ; Li, CM; Li, RA; Lieu, DK; Mak, SY; Tse, WW; Wong, AO; Wong, WS | 1 |
Kepp, O; Kroemer, G; Leduc, M; Liu, P; Martins, I; Tian, AL; Wu, Q; Zhao, L | 1 |
Abi-Gerges, N; Dumotier, B; Ghetti, A; Jordaan, P; Miller, PE; Traebert, M; Urban, L | 1 |
Gómez-Valent, M; Moreno-Ariño, M; Ortonobes Roig, S; Soler-Blanco, N; Torrente Jiménez, I; Van den Eynde Otero, E | 1 |
Brügel, M; Habler, K; Liebchen, U; Paal, M; Scharf, C; Schönermarck, U; Teupser, D; Vogeser, M | 1 |
Ehrlich, H; Elkbuli, A | 1 |
Adjadi, AA; Atakla, HG; Barry, MC; Houinato, AG; Houinato, DS; Noudohounsi, MMUD; Othon, GC; Sacca, H; Salami, AY | 1 |
Brouqui, P; Casalta, JP; Dubourg, G; Jacomo, V; La Scola, B; Lagier, JC; Raoult, D; Rolain, JM | 1 |
Aweeka, F; Gingrich, D; Huang, L; Marzan, F; Sok, V | 1 |
Guo, J; Li, W; Szendrey, M; Yang, T; Zhang, S | 1 |
Brañez-Condorena, A; Diaz-Arocutipa, C; Hernandez, AV | 1 |
Saint-Gerons, DM; Tabarés-Seisdedos, R | 1 |
Chi, G; Fitzgerald, C; Gibson, CM; Kazmi, SHA; Lee, JJ; Memar Montazerin, S; Shojaei, F | 1 |
Heitmann, S; Hill, AP; Kerr, N; Mangala, M; McArthur, JR; Perry, MD; TeBay, C; Vandenberg, JI; Windley, MJ | 1 |
Barry, H; Boly, R; Diendéré, AE; Drabo, MK; Ouédraogo, AR; Ouedraogo, AS; Ouédraogo, E; Poda, A; Rouamba, T; Sondo, A; Tahita, MC; Tarnagda, Z; Tinto, H; Traoré, I; Valea, I; Yaméogo, NV; Zoungrana, J | 1 |
Chotsiri, P; Hoglund, RM; Tarning, J; Watson, JA; White, NJ | 1 |
Beeson, JG; Burns, AL; Creek, DJ; Frölich, S; Gancheva, M; Goodman, CD; Ma, S; McFadden, GI; McLean, KT; O'Handley, R; Siddiqui, G; Sleebs, BE; Venter, H; Wilson, DW | 1 |
Giarolla, J; Parise-Filho, R; Polli, MC; Vassiliades, SV; Vaz, ES | 1 |
Aït Moussa, L; Alj, L; Khattabi, A; Meski, FZ; Sefiani, H; Soulaymani Bencheikh, R; Tebaa, A | 1 |
Aguiar, FC; Aguiar, RLO; Anschau, F; Bartolazzi, F; Batista, JDL; Bicalho, MAC; Costa, FR; Ferreira, MAP; Guimarães-Júnior, MH; Machado-Rugolo, J; Manenti, ERF; Marcolino, MS; Menezes, LSM; Nascimento, GF; Nogueira, MCA; Oliveira, LS; Pereira, DN; Pereira, EC; Pires, MC; Polanczyk, CA; Rios, DRA; Ruschel, KB; Schwarzbold, AV; Souza-Silva, MVR; Tofani, MGT; Vasconcelos, DH; Vasconcelos, IM; Vianna, HR; Ziegelmann, PK | 1 |
27 review(s) available for chloroquine and zithromax
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Malaria chemoprophylaxis in the age of drug resistance. I. Currently recommended drug regimens.
Topics: Animals; Antimalarials; Atovaquone; Azithromycin; Chloroquine; Drug Resistance; Health Planning Guidelines; Humans; Malaria, Falciparum; Mefloquine; Naphthoquinones; Plasmodium falciparum; Primaquine; Proguanil | 2001 |
Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy.
Topics: Africa South of the Sahara; Animals; Antimalarials; Azithromycin; Chloroquine; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Incidence; Malaria, Falciparum; Malaria, Vivax; Plasmodium falciparum; Plasmodium vivax; Pregnancy; Pregnancy Complications, Parasitic | 2008 |
Azithromycin for treating uncomplicated malaria.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Artesunate; Atovaquone; Azithromycin; Chloroquine; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Malaria, Falciparum; Malaria, Vivax; Male; Mefloquine; Proguanil; Pyrimethamine; Randomized Controlled Trials as Topic; Sulfadoxine; Treatment Failure | 2011 |
Azithromycin plus chloroquine: combination therapy for protection against malaria and sexually transmitted infections in pregnancy.
Topics: Adult; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Falciparum; Pregnancy; Pregnancy Complications, Infectious; Sexually Transmitted Diseases | 2011 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Monitoring, Physiologic; Pandemics; Patient Selection; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulins; Immunologic Factors; Indoles; Lopinavir; Oseltamivir; Pandemics; Pneumonia, Viral; Pyrazines; Ribavirin; Ritonavir; SARS-CoV-2; Withholding Treatment | 2020 |
[COVID-19 pandemia: Impact on the cariovascular system. Data of 1
Topics: Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Cardiomyopathies; Cardiovascular Diseases; Cerebrovascular Disorders; Chloroquine; Comorbidity; Coronary Disease; Coronavirus Infections; COVID-19; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Methylprednisolone; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Virus Internalization | 2020 |
Cardiovascular manifestations and treatment considerations in COVID-19.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Anticoagulants; Azithromycin; Betacoronavirus; Biomarkers; Cardiovascular Diseases; Chloroquine; Comorbidity; Coronavirus Infections; COVID-19; Cytokine Release Syndrome; Disseminated Intravascular Coagulation; Extracorporeal Membrane Oxygenation; Humans; Hydroxychloroquine; Immunosuppressive Agents; Influenza, Human; Lung; Myocardium; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; Troponin; Venous Thromboembolism | 2020 |
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Electrocardiography; Female; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Male; Middle Aged; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Prognosis; Risk Assessment | 2020 |
Coronavirus Disease 2019: Clinical Review.
Topics: Adenosine Monophosphate; Alanine; Amides; Animals; Antiviral Agents; Azithromycin; Betacoronavirus; Blood Coagulation Disorders; China; Chiroptera; Chloroquine; Coronavirus Infections; COVID-19; Glucocorticoids; Humans; Hydroxychloroquine; Infectious Disease Incubation Period; Lopinavir; Lung; Pandemics; Pneumonia, Viral; Prognosis; Pyrazines; Radiography, Thoracic; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Symptom Assessment | 2020 |
Targeting lymphocyte Kv1.3-channels to suppress cytokine storm in severe COVID-19: Can it be a novel therapeutic strategy?
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Cytokines; Drug Delivery Systems; Humans; Kv1.3 Potassium Channel; Lymphocytes; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severity of Illness Index | 2020 |
Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Biological Products; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Serotherapy; Humans; Hydroxychloroquine; Immunization, Passive; Non-Randomized Controlled Trials as Topic; Pandemics; Pneumonia, Viral; Protease Inhibitors; Protein-Tyrosine Kinases; Randomized Controlled Trials as Topic; Respiration, Artificial; SARS-CoV-2; Viral Load | 2020 |
Antimalarial and cytotoxic drugs on COVID-19 and the cardiovascular burden: Literature review and lessons to be learned.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Azithromycin; Cardiovascular Diseases; Chemically-Induced Disorders; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; SARS-CoV-2 | 2021 |
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chemical and Drug Induced Liver Injury; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; Endosomes; Humans; Hydrogen-Ion Concentration; Hydroxychloroquine; Intracellular Membranes; Lysosomes; Membrane Lipids; Models, Biological; Pandemics; Phospholipids; Pneumonia, Viral; SARS-CoV-2; Surface-Active Agents; Virus Internalization | 2020 |
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Bayes Theorem; Bias; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Humans; Hydroxychloroquine; Risk; SARS-CoV-2; Standard of Care; Survival Analysis | 2021 |
Modeling Potential Autophagy Pathways in COVID-19 and Sarcoidosis.
Topics: Angiotensin-Converting Enzyme Inhibitors; Autophagy; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Host-Pathogen Interactions; Humans; Isoniazid; Lung; Pandemics; Pneumonia, Viral; Pulmonary Edema; Rifampin; Sarcoidosis; SARS-CoV-2; Severe Acute Respiratory Syndrome; Severity of Illness Index | 2020 |
Impact of Hydroxychloroquine/Chloroquine in COVID-19 Therapy: Two Sides of the Coin.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Drug Synergism; Humans; Hydroxychloroquine; Immunologic Factors; Pandemics; Pneumonia, Viral; SARS-CoV-2; Treatment Outcome | 2020 |
Chloroquine and hydroxychloroquine for COVID-19: Perspectives on their failure in repurposing.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Drug Repositioning; Humans; Hydroxychloroquine; Long QT Syndrome; Treatment Outcome; Viral Load | 2021 |
Efficacy of chloroquine or hydroxychloroquine in COVID-19 patients: a systematic review and meta-analysis.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Hospitalization; Humans; Hydroxychloroquine; Randomized Controlled Trials as Topic; Treatment Outcome | 2021 |
Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients: authors' response.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome | 2021 |
Prevention and treatment of COVID-19: Focus on interferons, chloroquine/hydroxychloroquine, azithromycin, and vaccine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Interferons; Treatment Outcome | 2021 |
A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; Treatment Outcome | 2020 |
Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; ERG1 Potassium Channel; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Off-Label Use; Ritonavir | 2021 |
QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Observational Studies as Topic; Ritonavir | 2021 |
Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Network Meta-Analysis; Randomized Controlled Trials as Topic; Respiration, Artificial | 2021 |
Drug repositioning in the COVID-19 pandemic: fundamentals, synthetic routes, and overview of clinical studies.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; Dexamethasone; Drug Repositioning; Humans; Hydroxychloroquine; Ivermectin; Methylprednisolone; Pandemics; Reproducibility of Results; SARS-CoV-2 | 2023 |
16 trial(s) available for chloroquine and zithromax
Article | Year |
---|---|
Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparum.
Topics: Administration, Oral; Adolescent; Adult; Azithromycin; Chloroquine; Drug Administration Schedule; Drug Resistance; Humans; Malaria, Falciparum; Pilot Projects | 1994 |
A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India.
Topics: Adolescent; Adult; Aged; Antimalarials; Azithromycin; Chloroquine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; India; Malaria, Falciparum; Male; Middle Aged | 2005 |
A double-blind, randomized study of azithromycin compared to chloroquine for the treatment of Plasmodium vivax malaria in India.
Topics: Adult; Aged; Animals; Antimalarials; Azithromycin; Chloroquine; Double-Blind Method; Drug Administration Schedule; Female; Humans; Malaria, Vivax; Male; Middle Aged; Parasitemia; Plasmodium vivax; Primaquine; Treatment Outcome | 2005 |
Lack of a pharmacokinetic interaction between azithromycin and chloroquine.
Topics: Adult; Animals; Antimalarials; Area Under Curve; Azithromycin; Chloroquine; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; Humans; Malaria, Falciparum; Male; Middle Aged | 2006 |
A longitudinal trial comparing chloroquine as monotherapy or in combination with artesunate, azithromycin or atovaquone-proguanil to treat malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Atovaquone; Azithromycin; Child, Preschool; Chloroquine; Drug Combinations; Drug Resistance; Endpoint Determination; Female; Genotyping Techniques; Humans; Infant; Longitudinal Studies; Malaria; Male; Proguanil | 2012 |
Creative solutions to extraordinary challenges in clinical trials: methodology of a phase III trial of azithromycin and chloroquine fixed-dose combination in pregnant women in Africa.
Topics: Africa; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Malaria; Pregnancy; Pregnancy Complications, Infectious | 2013 |
Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets.
Topics: Adolescent; Adult; Africa South of the Sahara; Antimalarials; Azithromycin; Biological Availability; Child; Child, Preschool; Chloroquine; Drug Combinations; Female; Humans; Infant; Malaria, Falciparum; Male; Tablets; United States | 2014 |
Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children.
Topics: Antimalarials; Azithromycin; Child, Preschool; Chloroquine; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Humans; Incidence; Longitudinal Studies; Malaria; Malawi; Male; Respiratory Tract Infections; Risk | 2014 |
Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Drug Therapy, Combination; Female; Humans; Malaria, Falciparum; Male; Mefloquine; Middle Aged; Parasitemia; Plasmodium falciparum; Polymerase Chain Reaction; Treatment Outcome; Uganda; Young Adult; Zambia | 2014 |
Sulphadoxine-pyrimethamine plus azithromycin for the prevention of low birthweight in Papua New Guinea: a randomised controlled trial.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Low Birth Weight; Infant, Newborn; Malaria; Papua New Guinea; Pregnancy; Pregnancy Complications, Parasitic; Pyrimethamine; Single-Blind Method; Sulfadoxine; Young Adult | 2015 |
Comparison of azithromycin plus chloroquine versus artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in children in Africa: a randomized, open-label study.
Topics: Africa South of the Sahara; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Azithromycin; Child; Child, Preschool; Chloroquine; Drug Combinations; Ethanolamines; Female; Fluorenes; Humans; Infant; Malaria, Falciparum; Male | 2015 |
Malaria preventive therapy in pregnancy and its potential impact on immunity to malaria in an area of declining transmission.
Topics: Adult; Antibodies, Protozoan; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Erythrocytes; Female; Humans; Malaria, Falciparum; Papua New Guinea; Pregnancy; Pregnancy Complications, Parasitic; Pyrimethamine; Sulfadoxine; Young Adult | 2015 |
Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial.
Topics: Adolescent; Adult; Azithromycin; Chloroquine; Drug Combinations; Female; Humans; Infant, Newborn; Intention to Treat Analysis; Malaria, Falciparum; Pregnancy; Pregnancy Outcome; Pyrimethamine; Sulfadoxine; Treatment Outcome; Young Adult | 2016 |
Parasitological Clearance Rates and Drug Concentrations of a Fixed Dose Combination of Azithromycin-Chloroquine in Asymptomatic Pregnant Women with Plasmodium Falciparum Parasitemia: An Open-Label, Non-Comparative Study in Sub-Saharan Africa.
Topics: Adolescent; Adult; Africa South of the Sahara; Asymptomatic Diseases; Azithromycin; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Kaplan-Meier Estimate; Malaria, Falciparum; Parasite Load; Parasitemia; Plasmodium falciparum; Pregnancy; Treatment Outcome; Young Adult | 2016 |
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Brazil; Chloroquine; Coronavirus Infections; COVID-19; Disease Outbreaks; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Oseltamivir; Pandemics; Pneumonia, Viral; SARS-CoV-2; Tertiary Care Centers | 2020 |
An open label study of the safety and efficacy of a single dose of weekly chloroquine and azithromycin administered for malaria prophylaxis in healthy adults challenged with 7G8 chloroquine-resistant Plasmodium falciparum in a controlled human malaria inf
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Drug Combinations; Drug Resistance; Female; Humans; Malaria, Falciparum; Male; Middle Aged; Plasmodium falciparum; Young Adult | 2020 |
90 other study(ies) available for chloroquine and zithromax
Article | Year |
---|---|
In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin.
Topics: Amodiaquine; Animals; Antimalarials; Azithromycin; DNA, Protozoan; Drug Resistance; Erythrocytes; Humans; Malaria, Falciparum; Models, Structural; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins | 2007 |
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
Topics: Animals; Antimalarials; Artemisinins; Artesunate; Azithromycin; Clinical Trials, Phase II as Topic; Drug Evaluation; Drug Interactions; Drug Therapy, Combination; Humans; Malaria, Falciparum; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinine; Sesquiterpenes | 2007 |
Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening.
Topics: Animals; Antimalarials; Benzothiazoles; Diamines; Drug Evaluation, Preclinical; Erythrocytes; Fluorescent Dyes; Humans; Hypoxanthine; Organic Chemicals; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinolines; Reproducibility of Results; Sensitivity and Specificity | 2007 |
Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Drug Resistance; Flow Cytometry; Green Fluorescent Proteins; Plasmodium falciparum; Protein Synthesis Inhibitors; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Doxycycline; Inhibitory Concentration 50; Minocycline; Parasitic Sensitivity Tests; Plasmodium falciparum; Tetracycline; Tetracyclines; Tigecycline | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
An automated, polymer-assisted strategy for the preparation of urea and thiourea derivatives of 15-membered azalides as potential antimalarial chemotherapeutics.
Topics: Antimalarials; Automation; Azithromycin; Drug Resistance, Multiple; Inhibitory Concentration 50; Macrolides; Molecular Structure; Plasmodium falciparum; Structure-Activity Relationship; Thiourea; Urea | 2011 |
Antimalarial activity of 9a-N substituted 15-membered azalides with improved in vitro and in vivo activity over azithromycin.
Topics: Amides; Amines; Aminoquinolines; Animals; Antimalarials; Azithromycin; Cell Line, Tumor; Drug Resistance; Erythromycin; Humans; Macrolides; Malaria; Male; Mice; Microsomes, Liver; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum; Rats; Structure-Activity Relationship | 2012 |
Novel hybrid molecules based on 15-membered azalide as potential antimalarial agents.
Topics: Aminoquinolines; Antimalarials; Azithromycin; Cell Line; Chloroquine; Humans; Macrolides; Malaria; Plasmodium falciparum | 2012 |
Design, synthesis, and in vitro activity of novel 2'-O-substituted 15-membered azalides.
Topics: Anti-Bacterial Agents; Antimalarials; Aza Compounds; Cell Line, Tumor; Chloroquine; Drug Resistance; Erythromycin; Gram-Positive Bacteria; Humans; Plasmodium falciparum; Quinolines; Structure-Activity Relationship | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Antimalarial activities of 6-iodouridine and its prodrugs and potential for combination therapy.
Topics: Animals; Antimalarials; CHO Cells; Cricetinae; Cricetulus; Drug Interactions; Drug Resistance; Female; Mice; Orotidine-5'-Phosphate Decarboxylase; Plasmodium berghei; Plasmodium falciparum; Prodrugs; Uridine | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Evaluation, Preclinical; Drug Repositioning; HEK293 Cells; Host-Pathogen Interactions; Humans; Immunity, Innate; Mass Spectrometry; Molecular Targeted Therapy; Pandemics; Pneumonia, Viral; Protein Binding; Protein Biosynthesis; Protein Domains; Protein Interaction Mapping; Protein Interaction Maps; Receptors, sigma; SARS-CoV-2; SKP Cullin F-Box Protein Ligases; Vero Cells; Viral Proteins | 2020 |
Chloroquine fumardiamides as novel quorum sensing inhibitors.
Topics: Amides; Anti-Bacterial Agents; Chloroquine; Chromobacterium; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Quorum Sensing; Structure-Activity Relationship | 2020 |
Activity of azithromycin (CP-62,993) and erythromycin against chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum in vitro.
Topics: Animals; Antiprotozoal Agents; Azithromycin; Chloroquine; Drug Interactions; Drug Resistance; Erythromycin; Plasmodium falciparum | 1992 |
Antimalarial activity of azithromycin and erythromycin against Plasmodium berghei.
Topics: Animals; Antiprotozoal Agents; Azithromycin; Chloroquine; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Erythromycin; Malaria; Male; Mice; Plasmodium berghei; Specific Pathogen-Free Organisms | 1993 |
Adverse effects of antimalarial prophylactic drugs: an important consideration in the risk-benefit equation.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Atovaquone; Azithromycin; Chloroquine; Drug Therapy, Combination; Humans; Malaria; Mefloquine; Naphthoquinones; Plasmodium falciparum; Plasmodium vivax; Primaquine; Proguanil; Pyrimethamine; Risk Assessment | 1998 |
Azithromycin: antimalarial profile against blood- and sporozoite-induced infections in mice and monkeys.
Topics: Animals; Anti-Bacterial Agents; Antimalarials; Azithromycin; Chloroquine; Doxycycline; Erythromycin; Female; Macaca mulatta; Malaria; Male; Mice; Parasitemia; Plasmodium cynomolgi; Plasmodium yoelii; Primaquine; Pyrimethamine | 2000 |
Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin.
Topics: Ampicillin; Azithromycin; Cell Culture Techniques; Cell Membrane; Chloroquine; Lysosomes; Macrophages; Models, Biological; Phthalimides; Pivampicillin | 2003 |
Azithromycin/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig.
Topics: Action Potentials; Anesthesia; Animals; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Blood Pressure; Chloroquine; Dose-Response Relationship, Drug; Guinea Pigs; Heart; Heart Rate; Male | 2007 |
Lysosomotropic drugs inhibit maturation of transforming growth factor-beta.
Topics: Amodiaquine; Animals; Azithromycin; Blotting, Western; Bronchoalveolar Lavage Fluid; Cell Line; Cell Line, Tumor; Chloroquine; Enzyme-Linked Immunosorbent Assay; Epithelial Cells; Furin; Humans; Hydroxychloroquine; Kinetics; Lysosomes; Mice; Mice, Inbred C57BL; Phosphorylation; Stem Cells; Transforming Growth Factor beta | 2008 |
Pharmacokinetic properties of azithromycin in pregnancy.
Topics: Adult; Antimalarials; Area Under Curve; Azithromycin; Chloroquine; Chromatography, High Pressure Liquid; Drug Combinations; Female; Half-Life; Humans; Intestinal Absorption; Models, Statistical; Papua New Guinea; Pregnancy; Pyrimethamine; Sulfadoxine; Tandem Mass Spectrometry; Young Adult | 2010 |
Quinine for the treatment of malaria in pregnancy.
Topics: Animals; Antimalarials; Azithromycin; Chloroquine; Clindamycin; Drug Therapy, Combination; Female; Humans; Malaria; Plasmodium falciparum; Pregnancy; Pregnancy Complications, Infectious; Quinine | 2010 |
In vivo and in vitro antimalarial properties of azithromycin-chloroquine combinations that include the resistance reversal agent amlodipine.
Topics: Amlodipine; Animals; Antimalarials; Azithromycin; Chloroquine; Drug Interactions; Female; Mice; Parasitic Sensitivity Tests; Plasmodium falciparum | 2011 |
Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite.
Topics: Animals; Azithromycin; CD8-Positive T-Lymphocytes; Chloroquine; Erythrocytes; Female; Liver; Malaria; Malaria Vaccines; Mice; Mice, Inbred C57BL; Parasite Load; Parasitemia; Plasmodium berghei; Sporozoites; Vaccination; Vaccines, Attenuated | 2011 |
In vitro activity of Pheroid vesicles containing antibiotics against Plasmodium falciparum.
Topics: Antimalarials; Azithromycin; Chloroquine; Drug Delivery Systems; Drug Resistance; Erythromycin; Inhibitory Concentration 50; Lipids; Particle Size; Plasmodium falciparum; Solubility; Time Factors | 2012 |
Impairment of lysosomal functions by azithromycin and chloroquine contributes to anti-inflammatory phenotype.
Topics: Animals; Anti-Inflammatory Agents; Arachidonic Acid; Azithromycin; Blotting, Western; Cell Line; Cell Survival; Chloroquine; Dinoprostone; Enzyme Inhibitors; Flow Cytometry; Hydrogen-Ion Concentration; Interleukin-6; Lipopolysaccharides; Lysosomes; Macrolides; Macrophages; Mice; Microscopy, Confocal; Proton-Translocating ATPases; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2012 |
Chemobiosynthesis of new antimalarial macrolides.
Topics: Antimalarials; Azithromycin; Chloroquine; Drug Resistance; Erythromycin; Macrolides; Malaria; Parasitic Sensitivity Tests; Plasmodium berghei; Plasmodium falciparum | 2013 |
Scrub typhus and malaria co-infection causing severe sepsis.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Chloroquine; Coinfection; Doxycycline; Enzyme-Linked Immunosorbent Assay; Female; Fever; Humans; Immunoglobulin M; Malaria; Middle Aged; Norepinephrine; Orientia tsutsugamushi; Plasmodium vivax; Scrub Typhus; Sepsis; Severity of Illness Index; Treatment Outcome | 2014 |
Identification of hepatic phospholipidosis inducers in sandwich-cultured rat hepatocytes, a physiologically relevant model, reveals altered basolateral uptake and biliary excretion of anionic probe substrates.
Topics: Amiodarone; Animals; Anions; Azithromycin; Biliary Tract; Cells, Cultured; Chloroquine; Desipramine; Fluorobenzenes; Gentamicins; Hepatocytes; Male; Models, Biological; Phospholipids; Pyrimidines; Rats; Rats, Wistar; Rosuvastatin Calcium; Sulfonamides; Taurocholic Acid | 2014 |
Unexplained benefits of antibiotics in childhood: empiricism in need of enlightenment.
Topics: Antimalarials; Azithromycin; Chloroquine; Female; Gastrointestinal Diseases; Humans; Malaria; Male; Respiratory Tract Infections | 2014 |
Human babesiosis in Southeast China: A case report.
Topics: Administration, Intravenous; Anemia, Hemolytic; Anti-Bacterial Agents; Azithromycin; Babesiosis; C-Reactive Protein; China; Chloroquine; Clindamycin; Female; Fever; Humans; Middle Aged; Neutropenia; Thrombocytopenia | 2018 |
Topics: Anti-Bacterial Agents; Antimalarials; Artemether; Artemisinins; Atovaquone; Azithromycin; Chloroquine; Doxycycline; Ethanolamines; Fluorenes; Humans; India; Lumefantrine; Malaria, Falciparum; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2017 |
Chloroquine as a prophylactic agent against COVID-19?
Topics: Animals; Antimalarials; Antiviral Agents; Azithromycin; Betacoronavirus; Chlorocebus aethiops; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Pre-Exposure Prophylaxis; SARS-CoV-2; Vero Cells | 2020 |
Chloroquine and Hydroxychloroquine for the Prevention or Treatment of COVID-19 in Africa: Caution for Inappropriate Off-label Use in Healthcare Settings.
Topics: Antimalarials; Antirheumatic Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Coronavirus Infections; COVID-19; COVID-19 Testing; Drug Repositioning; Humans; Hydroxychloroquine; Off-Label Use; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Sample Size; SARS-CoV-2; Treatment Outcome; United States | 2020 |
Some drugs for COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Drug Combinations; Drug Repositioning; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Neuraminidase; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2 | 2020 |
Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
Topics: Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxychloroquine; Long QT Syndrome; Pharmacovigilance; Torsades de Pointes; United States | 2021 |
Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Topics: Azithromycin; Betacoronavirus; Cardiovascular Diseases; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Torsades de Pointes | 2020 |
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Electrocardiography; Follow-Up Studies; Humans; Hydroxychloroquine; Incidence; Pandemics; Pneumonia, Viral; Prospective Studies; Risk Factors; SARS-CoV-2; United States | 2020 |
COVID-19 and (hydroxy)chloroquine-azithromycin combination: Should we take the risk for our patients?
Topics: Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Drug Therapy, Combination; Humans; Hydroxychloroquine; Long QT Syndrome; Mental Disorders; Pandemics; Pneumonia, Viral; Risk Factors | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infections; COVID-19; Dehydration; Drug Interactions; Electrocardiography; Humans; Hydroxychloroquine; Long QT Syndrome; Pandemics; Pneumonia, Viral; Risk Assessment; Water-Electrolyte Imbalance | 2020 |
Additional safety consideration for azithromycin in the management of SARS-CoV-2 infection.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Repurposing of chloroquine and some clinically approved antiviral drugs as effective therapeutics to prevent cellular entry and replication of coronavirus.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Azithromycin; Chloroquine; Drug Repositioning; Humans; Lopinavir; Molecular Docking Simulation; Severe acute respiratory syndrome-related coronavirus; Virus Internalization; Virus Replication | 2021 |
COVID-19 and toxicity from potential treatments: Panacea or poison.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome | 2020 |
An evaluation of co-use of chloroquine or hydroxychloroquine plus azithromycin on cardiac outcomes: A pharmacoepidemiological study to inform use during the COVID19 pandemic.
Topics: Adolescent; Adult; Aged; Azithromycin; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Heart Diseases; Humans; Hydroxychloroquine; Male; Middle Aged; Pharmacoepidemiology; Retrospective Studies; Risk Factors; Young Adult | 2021 |
Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians (Version 1).
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; SARS-CoV-2; United States | 2020 |
Mycobacterium abscessus Clearance by Neutrophils Is Independent of Autophagy.
Topics: Adaptor Proteins, Signal Transducing; Anti-Bacterial Agents; Autophagy; Azithromycin; Case-Control Studies; Chemokine CCL4; Chloroquine; Cystic Fibrosis; Gene Expression Regulation; Host-Pathogen Interactions; Humans; Immunosuppressive Agents; Interleukin-8; Mycobacterium abscessus; Neutrophils; Phagocytosis; Primary Cell Culture; Reactive Oxygen Species; Signal Transduction; Sirolimus; Wortmannin | 2020 |
[Acute respiratory distress syndrome secondary to SARS-CoV-2 infection in an infant].
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Chloroquine; Combined Modality Therapy; Coronavirus Infections; COVID-19; Fatal Outcome; Female; Humans; Infant; Morocco; Multiple Organ Failure; Nasopharynx; Pandemics; Pneumonia, Viral; Respiration, Artificial; Respiratory Distress Syndrome; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral | 2020 |
Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Developing Countries; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Primary Health Care; SARS-CoV-2 | 2020 |
Update Alert: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
US Hydroxychloroquine, Chloroquine, and Azithromycin Outpatient Prescription Trends, October 2019 Through March 2020.
Topics: Anti-Infective Agents; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Databases, Pharmaceutical; Drug Prescriptions; Humans; Hydroxychloroquine; Outpatients; Pandemics; Pneumonia, Viral; Practice Patterns, Physicians'; Pre-Exposure Prophylaxis; Prescription Drug Monitoring Programs; SARS-CoV-2; United States | 2020 |
QT prolongation in a diverse, urban population of COVID-19 patients treated with hydroxychloroquine, chloroquine, or azithromycin.
Topics: Age Distribution; Aged; Aged, 80 and over; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; Electrocardiography; Female; Follow-Up Studies; Hospitalization; Humans; Hydroxychloroquine; Incidence; Long QT Syndrome; Male; Middle Aged; Pandemics; Pneumonia, Viral; Risk Assessment; Sex Distribution; Urban Population | 2020 |
Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2 | 2020 |
Update Alert 2: Should Clinicians Use Chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or Treatment of COVID-19? Living Practice Points From the American College of Physicians.
Topics: Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States | 2020 |
In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Topics: Amino Acid Motifs; Angiotensin-Converting Enzyme 2; Antiviral Agents; Azithromycin; Betacoronavirus; Binding Sites; Cathepsin L; Chloroquine; Coronavirus 3C Proteases; Coronavirus Infections; COVID-19; Cysteine Endopeptidases; Host-Pathogen Interactions; Humans; Hydroxychloroquine; Molecular Docking Simulation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Protein Binding; Protein Interaction Domains and Motifs; Protein Structure, Secondary; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Thermodynamics; Viral Nonstructural Proteins; Virus Attachment | 2020 |
SDRIFE-like rash associated with COVID-19, clinicopathological correlation.
Topics: Aged; Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Drug Eruptions; Exanthema; Female; Humans; Hydroxychloroquine | 2021 |
How to follow-up a patient who received tocilizumab in severe COVID-19: a case report.
Topics: Adult; Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Cytokines; Humans; Inflammation; Male; Off-Label Use; Pandemics; Pneumonia, Viral; Poland; SARS-CoV-2; Tomography, X-Ray Computed | 2020 |
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach.
Topics: Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Data Mining; Databases, Genetic; Drug Therapy, Combination; Gene Regulatory Networks; Humans; Hydroxychloroquine; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Toxicogenetics | 2020 |
Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Betacoronavirus; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Double-Blind Method; Drug Combinations; Humans; Hydroxychloroquine; Immunization, Passive; Lopinavir; Pandemics; Pneumonia, Viral; Registries; Ritonavir; SARS-CoV-2; Single-Blind Method; Stem Cell Transplantation | 2020 |
Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Cell Differentiation; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Embryonic Stem Cells; Humans; Mice; Myocytes, Cardiac; Pandemics; Pneumonia, Viral | 2020 |
Sex Differences in Reported Adverse Drug Reactions to COVID-19 Drugs in a Global Database of Individual Case Safety Reports.
Topics: Abdominal Pain; Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; Azithromycin; Chemical and Drug Induced Liver Injury; Chloroquine; COVID-19 Drug Treatment; Databases, Pharmaceutical; Diarrhea; Drug Combinations; Drug Eruptions; Drug Repositioning; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hydroxychloroquine; Long QT Syndrome; Lopinavir; Male; Nausea; Oseltamivir; Ritonavir; Sex Distribution; Sex Factors; Vomiting | 2020 |
Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 in Africa: Early Insights from the Democratic Republic of the Congo.
Topics: Adolescent; Adult; Asymptomatic Diseases; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Democratic Republic of the Congo; Drug Combinations; Enoxaparin; Female; Hospital Mortality; Hospitalization; Hospitals; Humans; Intensive Care Units; Lopinavir; Male; Middle Aged; Obesity; Pandemics; Patient Discharge; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Ritonavir; SARS-CoV-2; Severity of Illness Index; Treatment Outcome | 2020 |
A novel class of fast-acting antimalarial agents: Substituted 15-membered azalides.
Topics: Animals; Antimalarials; Azithromycin; Chloroquine; Dogs; Malaria; Mice; Plasmodium falciparum; Rats | 2021 |
Impact of Trump's Promotion of Unproven COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
Topics: Adenosine Monophosphate; Alanine; Azithromycin; Chloroquine; Communication; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Federal Government; Fraud; Humans; Hydroxychloroquine; Internet; Language; Mass Media; Pandemics; Pneumonia, Viral; Public Health; United States | 2020 |
Acute Guillain-Barré polyradiculoneuritis indicative of COVID-19 infection: a case report.
Topics: Adult; Atrial Fibrillation; Azithromycin; Betacoronavirus; Chloroquine; Clinical Laboratory Techniques; Combined Modality Therapy; Contraindications, Drug; Coronavirus Infections; COVID-19; COVID-19 Testing; Early Diagnosis; Guillain-Barre Syndrome; Humans; Male; Muscle Weakness; Nasopharynx; Olfaction Disorders; Oxygen Inhalation Therapy; Pandemics; Pneumonia, Viral; Quadriplegia; Respiration, Artificial; SARS-CoV-2; Urinary Incontinence | 2020 |
Investigational Treatments for COVID-19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions.
Topics: Action Potentials; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Models, Theoretical; Myocytes, Cardiac; Risk Factors; Ritonavir; Therapies, Investigational | 2021 |
Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.
Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Drug-Related Side Effects and Adverse Reactions; Humans; Myocardial Contraction; Myocytes, Cardiac; Pluripotent Stem Cells; Tissue Engineering; Ventricular Function | 2021 |
Lysosomotropic agents including azithromycin, chloroquine and hydroxychloroquine activate the integrated stress response.
Topics: Animals; Anti-Bacterial Agents; Azithromycin; Chloroquine; Humans; Hydroxychloroquine; Mice | 2021 |
Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Cardiotoxicity; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Myocytes, Cardiac; Risk Assessment; SARS-CoV-2; United States | 2021 |
[Clinical and pharmacological data in COVID-19 hospitalized nonagenarian patients].
Topics: Aged, 80 and over; Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Female; Hospitalization; Humans; Hydroxychloroquine; Male; Physical Functional Performance; Polypharmacy; Retrospective Studies; Risk Factors; Treatment Outcome | 2021 |
Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum
Topics: Adenosine; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Azithromycin; Chloroquine; Chromatography, Liquid; COVID-19; COVID-19 Drug Treatment; Furans; Humans; Hydroxychloroquine; Isotopes; Lopinavir; Pandemics; Pyrazines; Pyrroles; Ritonavir; SARS-CoV-2; Tandem Mass Spectrometry; Triazines | 2021 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Cardiovascular Diseases; Chloroquine; Comorbidity; COVID-19; COVID-19 Drug Treatment; Drug Interactions; Humans; Hydroxychloroquine; Long QT Syndrome; Myocytes, Cardiac; Receptors, Coronavirus; SARS-CoV-2; Torsades de Pointes | 2021 |
COVID-19 infection in pediatric subjects: study of 36 cases in Conakry.
Topics: Adolescent; Asymptomatic Infections; Azithromycin; Child; Child, Preschool; Chloroquine; COVID-19; COVID-19 Testing; Female; Guinea; Hospitalization; Humans; Infant; Male; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; Tomography, X-Ray Computed; Zinc | 2020 |
Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Dietary Supplements; Female; Humans; Male; Middle Aged; SARS-CoV-2; Treatment Outcome; Young Adult; Zinc | 2021 |
Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.
Topics: Anti-Bacterial Agents; Antimalarials; Azithromycin; Blood Specimen Collection; Chloroquine; Chromatography, High Pressure Liquid; Drug Monitoring; Edetic Acid; Humans; Hydroxychloroquine; Limit of Detection; Tandem Mass Spectrometry | 2021 |
COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antimalarials; Antiviral Agents; Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; ERG1 Potassium Channel; HEK293 Cells; Humans; Hydroxychloroquine; Potassium Channel Blockers | 2021 |
Torsade de pointes associated with chloroquine, hydroxychloroquine, and azithromycin: a retrospective analysis of individual case safety reports from VigiBase.
Topics: Adult; Aged; Azithromycin; Chloroquine; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Pharmacovigilance; Retrospective Studies; Torsades de Pointes | 2021 |
Pathophysiological metabolic changes associated with disease modify the proarrhythmic risk profile of drugs with potential to prolong repolarisation.
Topics: Acidosis; Azithromycin; Chloroquine; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Hypokalemia; Induced Pluripotent Stem Cells; SARS-CoV-2 | 2022 |
Assessment of Recovery Time, Worsening, and Death among Inpatients and Outpatients with COVID-19, Treated with Hydroxychloroquine or Chloroquine plus Azithromycin Combination in Burkina Faso.
Topics: Antiviral Agents; Azithromycin; Burkina Faso; Chloroquine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Inpatients; Outpatients; SARS-CoV-2 | 2022 |
Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.
Topics: Adult; Antimalarials; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19 Drug Treatment; DNA-Binding Proteins; Electrocardiography; Healthy Volunteers; Humans; Hydroxychloroquine; Long QT Syndrome; Pandemics; Pneumonia, Viral; Torsades de Pointes | 2022 |
Targeting malaria parasites with novel derivatives of azithromycin.
Topics: Animals; Antimalarials; Azithromycin; Chloroquine; Humans; Malaria; Malaria, Falciparum; Parasites; Plasmodium falciparum | 2022 |
Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
Topics: Azithromycin; Chloroquine; COVID-19; COVID-19 Drug Treatment; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxychloroquine; Morocco; Pharmacovigilance | 2023 |
Real-Life Data on Hydroxychloroquine or Chloroquine with or Without Azithromycin in COVID-19 Patients: A Retrospective Analysis in Brazil.
Topics: Aged; Arrhythmias, Cardiac; Azithromycin; Brazil; Chloroquine; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Female; Humans; Hydroxychloroquine; Male; Middle Aged; Retrospective Studies; SARS-CoV-2 | 2023 |